Evaluation of the use of betamethasone dipropionate with calcipotriol foam in patients with psoriasis
, 1
Abstract
Psoriasis is a chronic inflammatory dermatosis that requires topical treatment and care in most patients. Due to the current pace of life,
lack of time and unwillingness of patients to apply cosmetically unacceptable topical preparations, a person suffering from psoriasis
expects help and an indication of an easy-to-use and effective topical preparation. Currently, several topical treatments are available for
psoriasis patients. Although individualization of treatment remains important, there is a demand to achieve the best possible treatment
outcomes in the greatest number of patients. This paper presents and discusses cases involving the treatment of skin and scalp with
a foam formulation of betamethasone dipropionate with calcipotriol.
The aim of the study was to assess the use of combination of betamethasone dipropionate and calcipotriol in patients with psoriasis.
The observation was performed during a 3-month and 6-month treatment period with a topical combination of betamethasone dipropionate
and calcipotriol in foam, in patients with psoriasis. The principles of local treatment of psoriasis in daily dermatological practice
have been emphasized.
The paper discusses the use of the topical treatment with the combination of betamethasone dipropionate and calcipotriol in patients
with psoriasis in the long term outcome, with particular emphasis on proactive therapy.
Keywords: psoriasisfoambetamethasone dipropionate with calcipotriolrecommendations
References
- Rudnicka L, Olszewska M, Goldust M, et al. Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment. J Clin Med. 2021; 10(23).
- Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Dermatol Rev/Przegl Dermato. 2020; 107(2): 92–108.
- Megna M, Cinelli E, Camela E, et al. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020; 16(6): 599–620.
- Bewley AP, Shear NH, Calzavara-Pinton PG, et al. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019; 33(6): 1107–1115.
- Lebwohl M, Kircik L, Lacour JP, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021; 84(5): 1269–1277.
- Yan Ru, Jiang S, Wu Y, et al. Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review. Indian J Dermatol Venereol Leprol. 2016; 82(2): 135–144.
- Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015; 14(12): 1468–1477.
- Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. J Dermatolog Treat. 2016; 27(2): 120–127.
- Giovene GL, Giacomelli L. AIDA (Italian Association of Outpatient Dermatologists) Working Group. Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice? G Ital Dermatol Venereol. 2018; 153(6): 872–876.
- Menter A, Gold LS, Koo J, et al. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. Skinmed. 2017; 15(2): 119–124.
- Kim ES, Frampton JE. Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis. Drugs. 2016; 76(15): 1485–1492.
- Stein Gold L, Bagel J, Allenby K, et al. Betamethasone dipropionate spray 0.05% alleviates troublesome symptoms of plaque psoriasis. Cutis. 2020; 105(2): 97–102;E1.
- He C, Jin H, Liu X, et al. Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study. Dermatology. 2021; 237(4): 603–610.
- Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat. 2003; 14(1): 8–13.
- Kircik L, Stein Gold L, Teng J, et al. Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication. J Drugs Dermatol. 2020; 19(8): 723–732.
- Duvetorp A, Levin LÅ, Engerstedt Mattsson E, et al. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden. Acta Derm Venereol. 2019; 99(4): 393–399.
